Short-term efficacy and safety of edoxaban for venous thromboembolism after total hip or knee arthroplasty: a systematic review and meta-analysis.

依杜沙班 医学 入射(几何) 静脉血栓栓塞 不利影响 临床试验 随机对照试验 荟萃分析 内科学 外科 麻醉 华法林 血栓形成 达比加群 物理 光学 心房颤动
作者
JL Li,M Zhang,J-L Mai,Y-H Ma,D-W Gong,S Chen,J-C Xiao,Wang Hb
出处
期刊:DOAJ: Directory of Open Access Journals - DOAJ 卷期号:26 (15): 5540-5552
标识
DOI:10.26355/eurrev_202208_29425
摘要

Previous preliminary clinical trials have confirmed that edoxaban can be efficacious for venous thromboembolism (VTE). This meta-analysis was considered to evaluate edoxaban's short-term efficacy and safety for venous thromboembolism after arthroplasty.A comprehensive search was performed in these databases: PubMed, MEDLINE, Web of Science, and EMBASE on March 2022. All eligible trials should be randomized controlled trials (RCTs) when evaluating short-term efficacy and safety outcomes of edoxaban for VTE after total hip or knee arthroplasty.Nine RCTs with 4274 patients were involved in this meta-analysis. Edoxaban in the VTE group prevented the incidence of VTE and indicated valuable clinical efficacy. The incidence of adverse events (AEs) and adverse drug reactions (ADRs) in the edoxaban group was decreased than that in other groups. Edoxaban increased the incidence of all bleeding events. However, in the edoxaban group and other groups, there was no statistical difference between major bleeding events and clinically relevant non-major or minor bleeding events. Edoxaban subgroups included edoxaban 15 mg, edoxaban 30 mg and edoxaban 60 mg prevented the incidence of VTE. Edoxaban 30 mg and 60 mg group increased the risk of all bleeding events. Edoxaban 30 mg can increase the incidence of major bleeding events. There was no difference in clinically relevant non-major or minor bleeding events. Edoxaban 30 mg can decrease the incidence of AEs.Edoxaban was an efficacious and safe option to prevent and treat VTE in patients undergoing arthroplasty. However, we need further trials to explore edoxaban's long-term efficacy and safety.

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
大幅提高文件上传限制,最高150M (2024-4-1)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
端庄的如花完成签到 ,获得积分10
1秒前
lefcard完成签到,获得积分20
2秒前
研友_IEEE快到碗里来完成签到,获得积分10
3秒前
老西瓜完成签到,获得积分10
3秒前
陈龙平完成签到 ,获得积分10
3秒前
111完成签到,获得积分10
6秒前
weijun完成签到,获得积分10
7秒前
m123完成签到,获得积分10
8秒前
biolong545完成签到,获得积分10
10秒前
Htangmusi完成签到 ,获得积分10
11秒前
David完成签到,获得积分10
12秒前
159完成签到,获得积分10
14秒前
杜好好完成签到,获得积分10
15秒前
16秒前
chencai完成签到,获得积分20
16秒前
gelinhao完成签到,获得积分10
17秒前
人文完成签到 ,获得积分10
18秒前
夏虫完成签到,获得积分10
20秒前
20秒前
21秒前
21秒前
辛子完成签到 ,获得积分10
21秒前
centlay完成签到,获得积分0
22秒前
冷傲星月完成签到,获得积分10
23秒前
Dongcong完成签到 ,获得积分10
23秒前
sophyia完成签到,获得积分10
23秒前
Charles完成签到,获得积分10
24秒前
科研完成签到 ,获得积分10
25秒前
西门醉卉完成签到,获得积分10
26秒前
机灵柚子发布了新的文献求助200
26秒前
MM完成签到,获得积分10
26秒前
27秒前
majf完成签到,获得积分10
27秒前
等待的剑身完成签到,获得积分10
29秒前
青柠完成签到,获得积分10
30秒前
31秒前
云泽发布了新的文献求助10
31秒前
今后应助无与伦比采纳,获得10
32秒前
自信的孱发布了新的文献求助10
33秒前
曾欢完成签到,获得积分10
35秒前
高分求助中
One Man Talking: Selected Essays of Shao Xunmei, 1929–1939 1000
Yuwu Song, Biographical Dictionary of the People's Republic of China 700
[Lambert-Eaton syndrome without calcium channel autoantibodies] 520
The three stars each: the Astrolabes and related texts 500
Revolutions 400
Diffusion in Solids: Key Topics in Materials Science and Engineering 400
Phase Diagrams: Key Topics in Materials Science and Engineering 400
热门求助领域 (近24小时)
化学 材料科学 医学 生物 有机化学 工程类 生物化学 纳米技术 物理 内科学 计算机科学 化学工程 复合材料 遗传学 基因 物理化学 催化作用 电极 光电子学 量子力学
热门帖子
关注 科研通微信公众号,转发送积分 2451569
求助须知:如何正确求助?哪些是违规求助? 2124566
关于积分的说明 5406342
捐赠科研通 1853335
什么是DOI,文献DOI怎么找? 921734
版权声明 562273
科研通“疑难数据库(出版商)”最低求助积分说明 493051